Supplier News Breaks Archives
Wolters Kluwer Health adds NADAC info to Price Rx
January 29th, 2014
INDIANAPOLIS – Wolters Kluwer Health has released Price Rx v2.2, the latest version of its drug price analysis tool that now provides National Average Drug Acquisition Cost (NADAC) pricing information and other key enhancements.
The company said Tuesday that Price Rx users can now quickly reference the NADAC, the newly published national pricing benchmark from the Centers for Medicaid & Medicare Services (CMS), directly from within the application for a given drug product.
That information is fueled by data from the Medi-Span Federal Government Pricing File, which identifies similar NDCs not reported by CMS and extrapolates NADAC pricing to these NDCs.
On average, for every NDC CMS reports, Medi-Span extrapolates to an additional one or twos NDCs, Wolters Kluwer said, adding that such NDCS are readily identified and distinguished from the CMS-based NDCs.
"Price Rx is the only pricing analysis tool that provides both NADAC pricing and the extrapolated Medi-Span data," stated David Del Toro, vice president and general manager of clinical drug information for Wolters Kluwer Health Clinical Solutions. "As a result, Price Rx provides a more robust picture of NADAC pricing for affected NDCs as reported by Medi-Span, helping our customers with a variety of business needs."
Additional enhancements in the new release improve the user experience, as well as include more powerful custom reporting, streamline e-mail alert messaging, provide a more flexible product name search, and enable better organization of reports, with the ability to select reports as favorites.